DeOvo granted patent by US PTO

The active ingredient in the DeOvo head lice treatment, produced by Hatchtech Pty Ltd, has been granted a patent by the US Patent and Trademark Office.

The patent, Methods and compositions for controlling ectoparasites, granted on 3rd July 2012, relates to the DeOvo method of preventing lice eggs from hatching via a proprietary metal chelating agent.

The CEO of Hatchtech called the granting of the patent "a very important commercial milestone." Data on the clinical efficacy of DeOvo is currently being presented to relevant conferences. Phase III clinical trials are expected to commence in 2013.